F10 and interstitial lung disease: Use of FXa inhibitors was associated with a higher risk of incident ILD and use of dabigatran was associated with a nonsignificant difference in risk of incident ILD compared with warfarin after propensity score stabilized weighting; the higher risk of incident ILD associated with FXa inhibitors vs warfarin was observed in several high-risk subgroups.